HIV incidence, retention rate, and baseline predictors of HIV incidence and retention in a prospective cohort study of injection drug users in Xinjiang, China  by Zhang, Yuanzhi et al.
HIV incidence, retention rate, and baseline
predictors of HIV incidence and retention in a
prospective cohort study of injection drug users
in Xinjiang, China
Yuanzhi Zhang a, Hua Shan b, Jennifer Trizzino b, Yuhua Ruan c,
Geetha Beauchamp d, Benoıˆt Maˆsse d, Jun Ma a, Baoling Rui e,
Jun Wang e, Minsheng Liu a, Yunxia Wang c, Yixin He c,
Katharine Poundstone b, Yan Jiang c,
J. Brooks Jackson b,*, Yiming Shao c,**
International Journal of Infectious Diseases (2007) 11, 318—323
http://intl.elsevierhealth.com/journals/ijida Xinjiang Center for Disease Control and Prevention, Urumqi, China
b Johns Hopkins University School of Medicine, Carnegie 415, 600 North Wolfe Street, Baltimore, MD 21287, USA
c State Key Laboratory for Infectious Disease Prevention and Control, and National Center for AIDS/STD Control and
Prevention, Chinese Center for Disease Control and Prevention, 27 Nanwei Road, Xuanwu District, Beijing 100050, China
d Statistical Center for HIV/AIDS Research and Prevention (SCHARP), Seattle, WA, USA
eUrumqi Center for Disease Control and Prevention, Urumqi, China
Received 18 April 2006; received in revised form 16 August 2006; accepted 4 September 2006








Objective: To determine HIV seroincidence, study participant retention rate, and baseline
predictors of HIV incidence and study retention among high-risk injection drug users (IDUs) in
Xinjiang, China.
Methods: A total of 508 eligible seronegative high-risk IDUs were enrolled. Study participants
were tested for HIV-1 and counseled at the baseline, 6-month, and 12-month follow-up visits.
Sociodemographic and behavioral data were collected during each study visit. The HIV-1
incidence rate and the retention rate were analyzed as a function of sociodemographic,
behavioral, and recruitment variables.
Results: At 12 months of follow-up, the HIV-1 incidence rate was 8.8 per 100 person-years (95% CI
6.3—12.0%) and the participant retention rate was 93%. Marital status at baseline was the only
predictor of HIV incidence. No baseline variables were predictive of study retention.* Corresponding author. Tel.: +1 410 614 4966; fax: +1 410 614 2907.
** Corresponding author. Tel.: + 86 10 63166184; fax: +86 10 63154638.
E-mail addresses: Bjackso@jhmi.edu (J.B. Jackson), yshao@bbn.cn (Y. Shao).
1201-9712/$32.00 # 2006 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Conclusions: HIV incidence is high among IDUs in Xinjiang, China. Baseline predictors of incidence
and retention were minimal. The participant retention rate in this study is promising for the
undertaking of future HIV intervention studies.
# 2006 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.Introduction
The Chinese Ministry of Health (MOH) estimates that the
number of people currently living with HIV/AIDS in China is
650 000, corresponding to a prevalence rate of 0.05% at the
end of 2005.1 The MOH also estimated that injection drug
user (IDU)-related transmission accounted for 44.3% of HIV
infections, followed by heterosexual transmission (19.6%),
former commercial blood and plasma donations (10.7%), and
men who have sex with men (7.3%).1 While HIV prevalence in
China has not reached the levels seen in some other areas of
the world, high-risk behaviors associated with HIV, such as
needle sharing and unprotected sexual intercourse, are on
the rise.1
Heroin abuse first emerged as a problem in China’s border
region with Myanmar in Yunnan province in the late 1980s.2,3
The first HIV outbreak among injection drug users (IDUs) in
China was reported in Yunnan in 1989.4 By the end of 2002, all
31 of China’s provinces, municipalities, and autonomous
regions reported HIV infection among the population.1 The
reported number of drug users in China in 2003 was 1.0
million, with an annual increase rate of 11% increase in
the past four years.5 Sharing needles and syringes are the
predominant mode of HIV transmission, with IDUs accounting
for 71% of all HIV/AIDS reported cases in China.6 Although HIV
seroprevalence among the general Chinese population is still
relatively low, evidence shows that the epidemic is spreading
from high-risk populations such as IDUs and commercial sex
workers (CSWs) to the general population due to unprotected
sexual intercourse.1 In a country that contains more than 20%
of the world’s population, the potential exists for millions of
people to become HIV infected, despite a relatively low HIV
seroprevalence rate.
The first case of HIV infection was not identified in Xinjiang
Uighur Autonomous Region until 1995.7—9 However, Xinjiang
had the second highest number of reported cases of HIV/AIDS
in Chinawith the exception of Yunnan by the end of 2002.8 Ten
years into the HIV epidemic in China, HIV seroprevalence
among IDUs in some areas of Xinjiang has risen to 80%.1
According to the Xinjiang HIV surveillance data, drug-related
HIV transmission accounted for 75.5% of infections detected in
2003 with other modes of HIV transmission on the increase.8
However, very few studies have been conducted in China
to estimate HIV seroconversion incidence and study retention
rates among IDUs. The HIV Prevention Trials Network (HPTN)
Preparedness Study, HPTN 033, was a prospective cohort
study in Urumqi, Xinjiang to observe HIV seroincidence,
the study retention rate, and determine baseline predictors
of HIV incidence and study retention.
Methods
Inclusion criteria for subjects of the HPTN 033 study were the
following: (1) HIV-1 antibody negative at enrollment; (2)injected drugs at least three times per week in the previous
month or on at least three occasions in the previous three
months used injection equipment after another person; (3)
expressed a willingness to continue to participate for twelve
months; and (4) were able and willing to provide written
informed consent and sufficient locator information. Poten-
tial participants who had an obvious psychological/psychia-
tric disorder or any other condition that, in the opinion of the
investigator, would preclude provision of informed consent,
make participation in the study unsafe, or otherwise inter-
fere with achieving the study objectives were excluded from
the study. Initially, males and females had to be 18 years old
or older to be eligible, but this requirement was amended
near the end of the recruitment period in order to include 16-
and 17-year-old IDUs in the cohort.
The Xinjiang Uighur Autonomous Regional Institutional
Review Board (IRB) and the Western IRB in Olympia, Washing-
ton, USA, approved the study protocol before it started in
July 2002. All participants gave written informed consent
prior to enrollment.
Participant recruitment and retention
From July to December 2002 potential study subjects were
recruited by means of target sampling. Outreach workers
were recruited from the neighborhoods in and surrounding
Urumqi that were known to have high concentrations of
IDUs. Staff from the Urumqi Detoxification Center informed
drug users after their release that they could refer other
drug users or potentially enroll themselves into our study if
they had not been in the Detoxification Center within at
least the last month. Staff from the Urumqi Detoxification
Center referred recent releases. Study subjects were
allowed to refer a maximum of five peers. For each peer
that was referred and successfully enrolled into the study, a
study participant was given a small monetary incentive (US
$2.50).
One of the important objectives of the study was to
estimate the retention rate of high-risk IDUs in a standar-
dized HIV-related research study. A high retention rate in
longitudinal studies plays a crucial role in preventing poten-
tial biases due to missing data. Preparation for follow-up
visits began with obtaining sufficient locator information
from a participant at the enrollment visit. Each participant
was required to provide at least two different contact
sources (including different addresses or telephone num-
bers for the participant or his/her family members and
friends) to qualify for this study. After a participant was
enrolled, the data manager entered the locator information
into the Participant Information File System (PIFS) software
program. Whenever possible, the follow-up visits were
scheduled on the ‘target date’. Appointment reminder
procedures at follow-up every 6 months included: (1) study
staff sent a reminder letter or made a telephone call to
remind the participant 2—3 weeks before the scheduled
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Table 1 Univariate analysis of baseline predictors of HIV incidence












Sex Male 37/442 (8%) 413.0 9.0 6.3—12.3 1.13 0.43—2.93 0.807
Female 5/66 (8%) 62.0 8.1 2.6—18.8 1.00
Age <28 years old Yes 17/170 (10%) 157.0 10.8 6.3—17.3 1.41 0.75—2.66 0.326
No 25/338 (7%) 318.0 7.9 5.1—11.6 1.00
Race Uighur 25/235 (11%) 219.0 11.4 7.4—16.9 1.00 0.200
Han 13/206 (6%) 192.0 6.8 3.6—11.6 0.57 0.28—1.14
Other 4/67 (6%) 64.0 6.3 1.7—16.0 0.53 0.18—1.55
Marital status Married 6/134 (4%) 127.0 4.7 1.7—10.3 1.00 0.040
Single 32/292 (11%) 270.5 11.8 8.1—16.7 2.64 1.08—6.42
Live with
others
4/82 (5%) 77.5 5.2 1.4—13.2 1.10 0.30—3.96
College Yes 4/41 (10%) 37.0 10.8 2.9—27.7 1.29 0.44—3.72 0.642
No 38/467 (8%) 438.0 8.7 6.1—11.9 1.00
Employment status Employed
full time
13/209 (6%) 192.5 6.8 3.6—11.5 0.66 0.32—1.31 0.440
Employed to
some extent
5/49 (10%) 45.5 11.0 3.6—25.6 1.08 0.40—2.92
Unemployed 24/250 (10%) 237.0 10.1 6.5—15.1 1.00
Housing status Rent or own
house




2/28 (7%) 27.5 7.3 0.9—26.3 0.63 0.14—2.71
Live with
others
32/311 (10%) 287.0 11.1 7.6—15.7 1.00
Inject heroin Yes 42/508 (8%) 475.0 8.8 6.4—12.0
Inject tranquilizer Yes 5/49 (10%) 44.5 11.2 3.6—26.2 1.31 0.50—3.45 0.578
No 37/459 (8%) 430.5 8.6 6.1—11.8 1.00
Inject other Yes 6/83 (7%) 76.5 7.8 2.9—17.1 0.86 0.35—2.07 0.730




Yes 22/222 (10%) 213.5 10.3 6.5—15.6 1.35 0.73—2.5 0.355
No 20/286 (7%) 261.5 7.6 4.7—11.8 1.0
Share rinse water Yes 9/101 (9%) 94.0 9.6 4.4—18.2 1.10 0.51—2.35 0.799
No 33/407 (8%) 381.0 8.7 6.0—12.2 1.00
Share a cooker Yes 3/24 (13%) 21.5 14.0 2.9—40.8 1.66 0.49—5.64 0.413
No 39/484 (8%) 453.5 8.6 6.1—11.8 1.00
Use front/back-
loaded syringe
Yes 4/60 (7%) 57.5 7.0 1.9—17.8 0.75 0.26—2.15 0.595
No 38/448 (8%) 417.5 9.1 6.4—12.5 1.00
Sold sex Yes 8/57 (14%) 55.5 14.4 6.2—28.4 1.84 0.82—4.08 0.136
No 34/451 (8%) 419.5 8.1 5.6—11.3 1.00
Males Yes 8/49 (16%) 47.5 16.8 7.3—33.2 2.12 0.91—4.51 0.067
No 29/393 (7%) 365.5 7.9 5.3—11.4 1.00
Females Yes 0/8 (0%) 8.0 0.0 0.0—46.1 0.00 0.00—5.54 0.629
No 5/58 (9%) 54.0 9.3 3.0—21.6 1.00
HIV and injection drug users in Xinjiang, China 321visit. Study staff contacted the participant again one week
before the scheduled studyvisit to confirmthat theparticipant
planned tokeep theappointment. (2) If aparticipantmissedan
appointment, study staff called the participant on the same
day and rescheduled another appointment for the next work-
ing dayor as soon as possible. (3) If the participant couldnot be
rescheduled by telephone on the day of the missed visit, the
staff sent a letter to each address or called other contact
telephones listed in the PIFS. (4) During the first week in the
participant’s visit window, staff made telephone calls or sent
notifications. Meanwhile, outreach workers made a home/
street visit until the participant’s study visit was rescheduled.
During the 2—6weeks in the visit window, staff called all listed
telephone numbers once a week at varying times; outreach
workers made outreach visits every week. A data manager
continued to update contact log and locator information.
Outreach workers also checked drug detoxification centers
andprison systems todetermine the reason for amissed visit or
a loss to follow-up. Access to the PIFS was strictly protected
through a database security system. Prior to the initiation of
the study we informed the local public security officials about
the study. Theywere supportive of the study and agreed not to
target or interferewithparticipants. In addition, all study staff
at the clinic received GoodClinical Practice (GCP) training and
then signed a confidentiality agreement. Outreach workers
werealso trainednot todisclose any study-related information
to other personswhom they contacted in the process of finding
study participants in the community. A private counseling
roomwasused in interviewsand studyfiles containingpersonal
identifiers were kept in a locked room with access limited to
study personnel.
Data collection
Screening and enrollment procedures included several
steps. The prescreening interviews occurred during the
recruitment of IDUs in the field, to establish if there was
interest in participation, to communicate the location of the
research site, and to determine if transportation assistance
was needed. Screening at the study site confirmed eligibility
and consent was obtained to perform HIV-1 testing by
enzyme immunoassay (Vironostica HIV-Uni-Form II plus 0,
BioMerieux, The Netherlands) with confirmatory Western
Blot (Gene Labs Diagnostics, Singapore). A risk assessment
questionnaire was also administered at screening, which
focused on drug- and sex-related behavioral risk factors.
The questionnaire was designed to collect self-reported
sociodemographic data and behavioral information concern-
ing drug injection practices (types of drugs, frequency of
use, sharing experience) and characteristics of sexual beha-
vior with primary and casual partners. Given the relatively
low level of education among IDUs in China, we used a paper-
based survey administered by an interviewer. Social desir-
ability is a potential bias, but real-time logic was performed
by the interviewer for consistency. Quality control in our
study included the use of Study Specific Procedures and
Standard Operating Procedures for interviewing and for
training of staff, a private counseling room, and an ID
number for the data form.
Participants were instructed to return within 14 days for
their test results. At the return visit, after HIV results were
given, the HIV negative subjects were asked to give consentand were then enrolled into the cohort. HIV positive subjects
were counseled and referred to physicians and psychologists
working at the study site.
The design of the prospective HIV incidence cohort study
required follow-up study visits which were scheduled at 6 and
12 months for each enrolled participant. The 6-month and
12-month follow-up visits served the purpose of collecting
primary and secondary study endpoint data. The participants
were required to attend these follow-up visits within a 45-day
window period (15 days prior and 30 days after scheduled
date). At each time point, participants completed a follow-
up HIV risk assessment, received HIV pre-test and risk reduc-
tion counseling, underwent phlebotomy for HIV antibody
testing, and received their HIV test results and post-test
counseling (interim HIV counseling and testing could also
have been performed, at participant request, between
scheduled follow-up visits). During follow-up study visits,
the same procedure for HIV testing was administered includ-
ing confirmatory tests. The post-test visits were scheduled
for a time during a period of 7—14 days after the correspond-
ing follow-up visit. Subjects were paid 100 yuan (US $12.50)
for each study visit to cover transportation costs and their
time which could take up to a few hours per visit.
Participants who tested HIV positive during a follow-up
visit were counseled, referred to available medical and
psychosocial services, and referred to other available
research studies. Participants who tested HIV negative were
retained for follow-up over the next period of the study.
Study staff made ‘locator contacts’ with study partici-
pants at months 3 and 9. The locator contacts served the
purpose of enhancing retention by providing a mechanism to
confirm or update the participant’s locator information
(e.g., address, telephone number, name and address of
family members), confirming or re-scheduling the partici-
pant’s next follow-up visit, and reinforcing instructions for
the participant to contact the study site to update locator
information and/or, if needed, request HIV counseling and/
or testing between scheduled visits. In addition, any diffi-
culties experienced in contacting participants at these time
points served to trigger timely mobilization of outreach
efforts to ensure that participants were located in time
for their next scheduled follow-up visit. The contacts were
conducted in person at the study site, via telephone, or via
street/home outreach.
Statistical analysis
A sample size of 500was set in order to achieve a half-width of
about 2.5% for the 95% confidence interval for the HIV inci-
dence (based on a 12-month retention rate of 90% and a true
rate of 8%HIV seroincidence). Case report formswere faxed to
the HPTN statistical and data management center (Statistical
Center forHIV/AIDSResearch andPrevention, FredHutchinson
Cancer Research Center, Seattle, USA) where the data were
entered into the study database. All analyses were performed
using SAS software (SAS version 8.2). Data on the method of
recruitment were added to the database at a later date.
Descriptive statistics on sociodemographic and behavioral
characteristics of screened participants were computed.
TheHIV incidencedensity ratewas calculatedbasedonPoisson
distribution,withpersontimeof follow-upas thedenominator.
A proportional hazards model analysis was performed on the
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line predictors (sociodemographics, drug use, and sexual risk
behaviors) of HIV incidence. A logistic regression was used to
investigate the contribution of the baseline factors to the
study retention rate.
Results
The recruitment, screening, and enrollment of high-risk IDUs
occurred during a 6-month period beginning in July 2002 and
ending in December 2002. More than 781 IDUs were pre-
screened for eligibility and interest, and 228/781 (29%)
tested positive for HIV-1 antibody. A total of 508 eligible
high-risk IDUs gave consent for this study. The ages of the
participants ranged from 18 to 59 years, with a median of
29.3 years. The gender distribution was 87% male and 13%
female. The majority of the participants were of either
Uighur (46%) or Han (41%) ethnicity. Fifty-eight percent were
single, and most had no college education (92%). Forty-nine
percent were unemployed and 59% lived with parents. All
(100%) had injected drugs in the month prior to baseline and
reported having used heroin in the 3months prior to baseline.
There were no men who reported having had sex with men.
Participants were considered retained at the 12-month
visit if they completed the 12-month follow-up visit or if they
had seroconverted prior to the 12-month visit. Under this
definition, the overall retention rate was 93% (472/508) for
the 12-month visit. Therewere 66 (13%) participants who did
not complete the 6-month visit and 36 (7%) participants did
not complete the 12-month visit within the 45-day window
period. Univariate logistic regression analysis did not
identify any baseline predictors (sociodemographics, drug
use, and sexual risk behaviors) for retention. Of the 36
participants lost to follow-up, 16 were unable to be
contacted, eight died, seven missed their scheduled
appointment, three were incarcerated, and two refused
to further participate.
During the 12-month follow-up period, 42 HIV antibody
seroconversions were observed to have occurred within 475
person-years of risk with 18/42 seroconverting by the 6-
month visit. The observed HIV incidence rate was 8.8 per
100 person-years (95% CI 6.3—12.0%). Univariate proportional
hazard model analyses were performed on a discrete time
scale of semi-annual visits to identify the baseline predictors
(sociodemographics, drug use, and sexual risk behaviors).
Marital status (single vs. married, RR = 2.64, 95% CI 1.08—
6.42) was the only factor that was significantly associated
with HIV incidence (See Table 1). All reported having used
heroin, 49 reported having used tranquilizers, and 83
reported having used other drugs. Among those who sero-
converted to HIV positive, five reported having used tran-
quilizers and six reported having used other drugs. The risk
behavior category of being a male who sold sex (RR = 2.12,
95% CI 0.91—4.51) was marginally significantly associated
with HIV incidence. No baseline variable was predictive of
study retention.
Discussion
This study found that the HIV seroincidence rate during a
12-month follow-up among high-risk IDUs in Xinjiang was8.8 per 100 person-years (95% CI 6.3—12.0%). Only marital
status (being single) was a predictor for HIV seroconversion.
Previous smaller studies have reported HIV seroincidence
rates among other IDU populations in China. A study con-
ducted in three counties of Yunnan Province during 1992—
1994 found seroconversion rates from 0 to 25 per 100
person-years.10 Another study reported an HIV incidence
of 2.38 per 100 person-years among drug users during the
first follow-up period (February 1998—January 1999) and
6.86 per 100 person-years during the second follow-up
period (January—September 1999) in Pingxiang County of
Guangxi Province.11 A recent 12-month follow-up study in
Xichang County of Sichuan province found an HIV incidence
of 3.17 per 100 person-years (95% CI 0.98—5.37).12 The
study from Sichuan and our results from Xinjiang demon-
strate that HIV is spreading rapidly among IDUs in geo-
graphic areas other than Yunnan and Guangxi, the typical
epicenters of the HIV/AIDS epidemic in China. During the
period for the above studies, drug treatment and needle
and syringe exchange programs were not available to most
IDUs. Intervention programs, including expanded treatment
for drug abuse and harm-reduction strategies, should be
implemented in IDU populations to prevent the spread of
HIV infection.
The overall retention rate in this study was 93% for the
12-month visit. This is the first study in China to evaluate
the retention rate in a prospective cohort study of injecting
drug users. The retention methods used in the study were
designed borrowing experiences from other international
studies.13,14 Maintaining high retention rates is generally
believed to be more difficult when working with IDU indi-
viduals in prospective cohort studies. Some studies have
reported that approximately 25% of the participants were
lost to follow-up.15,16 Our results suggest that a well-
designed and thoroughly executed retention plan is key
to achieving high retention rates even when working with
a high-risk IDU population. No baseline participant char-
acteristics were found to significantly affect retention
in this study. Several studies have also found that HIV
high-risk behaviors are not associated with cohort reten-
tion.13—15,17
Limitations of this study include a possible selection and
recall bias. Because this study was restricted to high-risk IDUs
with the inclusion criteria, these results may not be repre-
sentative of the general IDU population in the region and
should be used with caution when applied to IDUs in other
regions. IDUs who injected drugs and shared injection equip-
ment less frequently than required by our inclusion criteria
were not included in this study. It is possible that if these IDUs
were included in the study, characteristics of drug injection
behavior (such as the frequency of injection and the fre-
quency of sharing equipment) might be found to be statis-
tically associated with HIV seroconversion. Underreporting of
risk behaviors in drug use and sexual activities by study
participants is possible, which could have limited the detec-
tion of a significant association between behavioral risk
variables and HIV incidence. In addition, since the time this
study was conducted, several programs for harm reduction
such as a needle exchange program, a methadone treatment
program, and a peer education and AIDS CARE program have
been initiated in Urumqi so the HIV incidence rates may
currently be different.
HIV and injection drug users in Xinjiang, China 323Our data strongly demonstrate that HIV is spreading
rapidly among high-risk IDUs in Xinjiang, China. The high
seroincidence and retention rates in this population offer the
opportunity to conduct randomized controlled trials for test-
ing the efficacy of harm reduction and HIV prevention inter-
ventions.
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